Association between the histological subtype of lung adenocarcinoma, EGFR/KRAS mutation status and the ALK rearrangement according to the novel IASLC/ATS/ERS classification

Oncology Letters

Volumn 11, Issue 4, 2016, Pages 2552-2558

  Dong, Yu Jie ^a   Cai, Yi Ran ^a   Zhou, Li Juan ^a   Su, Dan ^a   Mu, Jing ^a   Chen, Xue Jing ^a   Zhang, Li ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Histological subtype; International association for the study of lung cancer american thoracic society european respiratory society; Lung adenocarcinoma; Mutation status

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL CLASSIFICATION; DNA EXTRACTION; DNA SEQUENCE; FEMALE; GENE FUSION; GENE REARRANGEMENT; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATION; ONCOGENE K RAS; POLYMERASE CHAIN REACTION;

EID: 84960345479     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2016.4233     Document Type: Article

References (32)

1. Devesa SS, Bray F, Vizcaino AP and Parkin DM: International lung cancer trends by histologic type: Male:Female differences diminishing and adenocarcinoma rates rising. Int J Cancer 117: 294-299, 2005.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N and Manegold C: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27: 1227-1234, 2009.
4. Jorge SEDC, Kobayashi SS and Costa DB: Epidermal growth factor receptor (EGFR) mutations in lung cancer: Preclinical and clinical data. Braz J Med BiolRes 47: 929-939, 2014.
5. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et al; West Japan Oncology Group: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11: 121-128, 2010.
6. Motoi N, Szoke J, Riely GJ, Seshan VE, Kris MG, Rusch VW, Gerald WL and Travis WD: Lung adenocarcinoma: Modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 32: 810-827, 2008.
7. Yatabe Y, Koga T, Mitsudomi T and Takahashi T: CK20 expression, CDX2 expression, K-ras mutation and goblet cell morphology in a subset of lung adenocarcinomas. J Pathol 203: 645-652, 2004.
8. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al: EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004.
9. Riely GJ, Marks J and Pao W: KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 6: 201-205, 2009.
10. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566, 2007.
11. Berge EM, Lu X, Maxson D, Barón AE, Gadgeel SM, Solomon BJ, Doebele RC, Varella-Garcia M and Camidge DR: Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. Clinical Lung Cancer 14: 636-643, 2013.
12. Warth A, Muley T, Meister M, Stenzinger A, Thomas M, Schirmacher P, Schnabel PA, Budczies J, Hoffmann H and Weichert W: The novel histologic international association for the study of lung cancer/American thoracic society/European respiratory society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 30: 1438-1446, 2012.
13. Russell PA, Barnett SA, Walkiewicz M, Wainer Z, Conron M, Wright GM, Gooi J, Knight S, Wynne R, Liew D and John T: Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients. J Thorac Oncol 8: 461-468, 2013.
14. Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, Tsuruyama T, Travis WD, Date H and Haga H: Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: Analysis of 440 Japanese patients. J Thorac Oncology 8: 52-61, 2013.
15. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, et al: International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6: 244-285, 2011.
16. Yoshida A, Tsuta K, Nakamura H, Kohno T, Takahashi F, Asamura H, Sekine I, Fukayama M, Shibata T, Furuta K and Tsuda H: Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 35: 1226-1234, 2011.
17. Jokoji R, Yamasaki T, Minami S, Komuta K, Sakamaki Y, Takeuchi K and Tsujimoto M: Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J Clin Pathol 63: 1066-1070, 2010.
18. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions: The IASLC lung cancer staging project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2: 706-714, 2007.
19. Shimada Y, Saji H, Nomura M, Matsubayashi J, Yoshida K, Kakihana M, Kajiwara N, Ohira T and Ikeda N: Cancer stem cell-related marker expression in lung adenocarcinoma and relevance of histologic subtypes based on IASLC/ATS/ERS classification. Onco Targets Ther 6: 1597-1604, 2013.
20. Kosaka T, Yatabe Y, Onozato R, Kuwano H and Mitsudomi T: Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol 4: 22-29, 2009.
21. Cai YR, Zhang HQ, Qu Y, Mu J, Zhao D, Zhou LJ, Yan H, Ye JW and Liu Y: Expression of MET and SOX2 genes in non-small cell lung carcinoma with EGFR mutation. Oncol Rep 26: 877-885, 2011.
22. Franklin WA, Haney J, Sugita M, Bemis L, Jimeno A and Messersmith WA: KRAS mutation: Comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn 12: 43-50, 2010.
23. Yu DP, Dong YJ, Zhang HQ, Wang JH, Qu Y, Zhou LJ, Su D, Zhang LL, Zhao D and Cai YR: Differential expression of CRKL and AXL genes in lung adenocarcinoma subtypes according to the epidermal growth factor receptor and anaplastic lymphoma kinase gene status. Biomed Rep 2: 481-489, 2014.
24. Song Z, Zhu H, Guo Z, Wu W, Sun W and Zhang Y: Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients. Med Oncol 30: 645, 2013.
25. Tsuta K, Kawago M, Inoue E, Yoshida A, Takahashi F, Sakurai H, Watanabe S, Takeuchi M, Furuta K, Asamura H and Tsuda H: The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung cancer 81: 371-376, 2013.
26. Wang J, Dong Y, Cai Y, Zhou L, Wu S, Liu G, Su D, Li X, Qin N, Nong J, et al: Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status. J Cancer Res Clin Oncol 140: 453-460, 2014.
27. Zhang Y, Sun Y, Pan Y, Li C, Shen L, Li Y, Luo X, Ye T, Wang R, Hu H, et al: Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res 18: 1947-1953, 2012.
28. Kakegawa S, Shimizu K, Sugano M, Miyamae Y, Kaira K, Araki T, Nakano T, Kamiyoshihara M, Kawashima O and Takeyoshi I: Clinicopathological features of lung adenocarcinoma with KRAS mutations. Cancer 117: 4257-4266, 2011.
29. Rekhtman N, Ang DC, Riely GJ, Ladanyi M and Moreira AL: KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. Mod Pathol 26: 1307-1319, 2013.
30. Ignatius SH, Ziogas A and Zell JA: Primary signet-ring carcinoma (SRC) of the lung: A population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung. J Thorac Oncol 5: 420-427, 2010.
31. Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ et al: ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: An analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 19: 4273-4281, 2013.
32. Zhang X, Zhang S, Yang X, Yang J, Zhou Q, Yin L, An S, Lin J, Chen S, Xie Z, et al: Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 9: 188, 2010.